Evidence map›Paper›PMID 30936193›Full record

ArticleCold Spring Harbor molecular case studies2019

Detection of a cryptic

Jess F Peterson, Beth A Pitel, Stephanie A Smoley, James B Smadbeck, Sarah H Johnson, George Vasmatzis, Sarah J Koon, Matthew R Webley, Mary McGrath, Michael G Bayerl and 5 more

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cold Spring Harbor molecular case studies, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Detection ofBlood research · 2022
    Article
  3. Case Report: The First Report ofFrontiers in oncology · 2021
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Jess F PetersonDivision of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology.
Beth A PitelDivision of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology.
Stephanie A SmoleyDivision of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology.
James B SmadbeckCenter for Individualized Medicine-Biomarker Discovery, Mayo Clinic, Rochester, Minnesota 55905, USA.
Sarah H JohnsonCenter for Individualized Medicine-Biomarker Discovery, Mayo Clinic, Rochester, Minnesota 55905, USA.
George VasmatzisCenter for Individualized Medicine-Biomarker Discovery, Mayo Clinic, Rochester, Minnesota 55905, USA.
Sarah J KoonDivision of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology.
Matthew R WebleyDivision of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology.
Mary McGrathDivision of Pediatric Hematology/Oncology, Department of Pediatrics, Penn State Children's Hospital, Hershey, Pennsylvania 17033, USA.
Michael G BayerlDepartment of Pathology and Laboratory Medicine, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania 17033, USA.
Linda B BaughnDivision of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology.
Ross A RowseyDivision of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology.
Rhett P KetterlingDivision of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology.
Patricia T GreippDivision of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology.
Nicole L HoppmanDivision of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology.
Institut thématique Génétique, génomique et bioinformatique · FRMayo Clinic · USPenn State Milton S. Hershey Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematopoietic neoplasm involving the bone marrow and blood that accounts for ∼15% of childhood and 25% of adult ALL. Whereas multiple, recurrent genetic abnormalities have been described in T-ALL, their clinical significance is unclear or controversial. Importantly,

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsChild, PreschoolHigh-Throughput Nucleotide SequencingHumansIn Situ Hybridization, FluorescenceMaleNuclear Pore Complex ProteinsOncogene Proteins, FusionPrecursor T-Cell Lymphoblastic Leukemia-LymphomaProto-Oncogene Proteins c-ablSequence Analysis, DNATreatment OutcomeABL1 protein, humanNuclear Pore Complex ProteinsNUP214 protein, humanOncogene Proteins, FusionProto-Oncogene Proteins c-ablT-cell acute lymphoblastic leukemias

Identifiers

PMID30936193
PMCPMC6549564
OpenAlexW2931254234

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.